

Biochemical Genetics

Genetics in Medicine - 0504321

2022-2023 Second Semester

Dr. Osama Alsmadi


METABOLIC DISORDER DEFINITION

Metabolism refers to the ongoing biochemical processes that maintain the functioning of living organisms. It is the balance of two processes:


- Catabolism: Producing energy from breaking down larger molecules into smaller ones. For example, this may involve breaking down carbohydrate molecules into glucose.
- Anabolism: Consuming energy to build new cells, maintaining body tissues, and storing energy.

Examples of causes:


- > Genetics:
- > Organ dysfunction
- Mitochondrial dysfunction:



Metabolic Profile of Organs



3



BIOCHEMICAL DISEASES (BD), aka IEM

Carbohydrate Metabolism Disorder

Galactosemia

Glycerol Kinase Deficiency

Glycogen Storage Diseases

Amino Acid Disorders

Phenylketonuria

Tyrisonemia

Maple Syrup Urine Disease

Nonketotic Hyperglycinemia

Homocystinuria

Glutaric Acidemia Type I

Organic Acid Disorders

Propionic Acidemia

Isovaleric Acidemia

Methylmalonic Acidemia

Urea Cycle Defects

Carbamoyl phosphate synthetase I deficiency

Ornithine transcarbamylase deficiency

Citrillinemia

Argininosuccinic Aciduria

Argininemia

WHEN TO SUSPECT BD?

- Usually Normal infant at birth (term)
- Illness presentation within first 48 hours of age

FAMILY HISTORY

- Neonatal death of unclear etiology
- History of child with neurologic deterioration
- History of multiple miscarriages
- Consanguinity

CLINICAL PRESENTATION

- Poor oral intake &/or vomiting
- Lethargy coma, seizures,
- Hepatosplenomegaly, dysmorphic features
- Cataracts


Inborn Errors of Metabolism Categories		Incidence/ Inheritance	Enzyme Deficiency	Symptom Onset
Disorders of Carbohydrat e Metabolism	Galactosemia	1:40,000 AR	 Galactose-1-Phosphate Uridyltransferase (GALT) Galactose epimerase 	First few days of life
	Glycogen Storage Disease (Von Gierke)	1:100,000 AR	Glucose-6 - Phosphatase	By 2 years of age
Disorders of Amino Acid Metabolism	Phenylketonuria (PKU)	1:15,000 <mark>AR</mark>	 Phenylalinine Hydroxylase Biopterin defect 	First few months of life
	Maple Syrup Urine Disease	1:150,000 <mark>AR</mark>	Branched chain 3-Ketoacid Dehydrogenase Complex	3-5 days of age
	Tyrosinemi a type l	Rare AR	Fumarylacetoacetat e hydroxylase	Birth to first few months of life
	Glutaric Acidemia	1:30-40,000 <mark>AR</mark>	Glutaryl-CoA Dehydrogenase	Infancy or early childhood
	Urea Cycle Defects	1:30,000		Varies

CARBOHYDRATE METABOLISM DISORDERS

GALACTOSEMIA


- Autosomal recessive disorder of galactose metabolism
- Three forms: Classic galactosemia, Galactokinase deficiency, Galactose-4'-epimerase deficiency
- Screening: Measures GALT activity &/OR Galactose and Galactose-1-Phosphate
- Clinical Presentation: Lethargy, poor feeding, jaundice, cataracts, E. coli sepsis
- Diagnostic Test
 - Urinary reducing substances*
 - Whole blood or erythrocyte GALT activity and erythrocyte red cell galactose-1-phosphate
- Treatment: Strict dietary lactose /galactose restriction
- Long term Prognosis: Mild growth failure, learning disabilities, ataxia, tremor and verbal dyspraxia
 - Ovarian failure, also probable infertility in males

GALACTOSEMIA PATHWAY



Cataracts (late in childhood)

Diagnosis in Absence of Enzyme



Galactose-4'-Epimerase Deficiency

Cataracts, diarrhea, jaundice, intellectual disability and liver failure (first few months of life)

GLYCEROL KINASE DEFECTIENCY

- •X-linked recessive defect in glycerol kinase
- Clinical Presentation: Isolated Symptomatic: Lethargy, vomiting, acidosis, ketotic hypoglycemia
- Lab Findings: Pseudotriglyceridemia (elevated glycerol interferes with assay for triglycerides)
- Diagnostic studies: FISH analysis to assess for deletion
- Treatment: Manage SYMPTOMS as indicated by using corticosteroids, glucose infusion, or mineralocorticoids
- PROGNOSIS: Infantile form is associated with severe developmental delay

GLYCOGEN STORAGE DISEASE

Туре	Enzyme defect	Eponym	Hypoglycemia	Hyperlipidemia	Symptoms	Others
GSD type 1	Glucose-6-phosphatase	Von Gierke's	Yes	Yes	Growth failure	Lactic acidosis, hyperuricemia
GSD type 2	Acid maltase	Pompe's	No	No	Death by age ~ 2 years	Heart failure Myopathy
GSD type 3	Glycogen debrancher	Cori's or Forbes'	Yes	Yes		Myopathy
GSD type 4	Glycogen branching enzyme	Andersen	No	No	Failure to thrive, death at age ~ 5 years	Liver cirrhosis
GSD type 5	Muscle glycogen phosphorylase	McArdle	No	No		Renal failure by myoglobinuria
GSD type 6	Liver glycogen phosphorylase	Hers' disease	Yes	No		
GSD type 7	Muscle phosphofructokinase	Tarui's disease	No	No	Growth retardation	Hemolytic anemia
GSD type 9	Phosphorylase kinase PHKA2		No	Yes	Delayed motor development, growth retardation	
GSD type 11	Glucose transporter GLUT2	Fanconi-Bickel Syndrome	Yes	No		
GSD type 12	Aldolase A	Red cell aldolase deficiency	?	?		Exercise intolerance
GSD type 13	B-enolase		?	?		Exercise intolerance

VON GIERKE DISEASE (GSD 1A)

- Autosomal recessive defect in glucose-6-phosphatase → glycogen accumulates in the liver
- Clinical Presentation: Normal at birth. Hypoglycemia presents when infants start to sleep through the night (prolonged fasting). Hepatomegaly

May present in neonatal period

Diagnostic studies

- Liver biopsy glycogen and assay for enzyme
- DNA testing may obviate need for liver biopsy
- Treatment: Avoidance of fasting. Continuous nighttime feeds in infancy. Corn starch.

POMPE DISEASE (GSD 2)

Autosomal recessive disorder of

 α 1,4-glucosidase

- Clinical Presentation: Normal at birth. Then onset of muscle weakness, feeding and breathing difficulty
 - Infantile: dilated cardiomyopathy, failure to thrive, hypotonia, macroglossia

➤ Lab Findings:NO hypoglycemia!!!, 个CPK

- Diagnostic studies: Assay enzyme in lymphocytes, muscle or fibroblasts
- Treatment: Enzyme Replacement Therapy available
 - since 2006



DISORDERS OF AMINO ACIDS METABOLISM

PHENYLKETONEURIA (PKU)

- > Autosomal recessive disorder in which phenylalanine can not be converted to tyrosine
- > **Enzyme Defect:** Phenylalanine Hydroxylase (chromosome 12q24.1)
- Clinical Presentation: Normal at birth. > 50% affected infants present with the following signs:
 - > Vomiting, irritability, eczematoid rash, peculiar odor 'musty', fair-hair and skin
- Screening: Test for elevated levels of phenylalanine
- Diagnostic studies
 - > If positive screen, quantitative analysis of serum phenylalanine and tyrosine
- > Treatment: Limit dietary intake of phenylalanine.
 - > Followed by dietician and Phe levels are monitored closely
- Long term Prognosis: If untreated severe intellectual disability IQ < 30. Acquired microcephaly</p>
 - Damage becomes irreversible by 8 weeks of age

TYROSINEMIA

	Enzyme Defect	Clinical Presentation	Diagnosti c Studies	Treatment	Prognosis
Type I	Fumarylacetoacetate hydroxylase	Failure to thrive (FTT) Hepatomegaly Hepatoblastoma RTA Rickets	Succinylacetone in urine ↑ levels of tyrosine in plasma	Diet low in tyrosine and phenylalanin e -NTBC	Infants are affected early with high risk of mortality
Type II	Tyrosine Aminotransferase	Corneal ulcers or dendritic keratitis 50% with intellectual disability Red papular lesions on their palms and soles No liver toxicity		Diet low in tyrosine	pyruvate D NTBC ate D cetate Al reduction Succinylacetoacetate acetate decarboxylation

MAPLE SYRUP UTINE DISEASE

- Autosomal recessive disorder of branched chain amino acid metabolism (valine, leucine and isoleucine
- > Enzyme Defect:

Defect in oxidative decarboxylation of ketoacids

Clinical Presentation: Feeding difficulty, irregular respirations, loss of Moro reflex, bicyclinc motion of legs/swimming with arms, severe seizures, opisthotonos and rigidity

Diagnostic Test

- Urine organic acids branched chain 2-keto and 2-hydroxy acids
- Presence of alloisoleucine is diagnostic
- Treatment: Strict dietary control of leucine, isoleucine and valine restriction

Long term Prognosis:

Rapid progression to death within 2-4 weeks if no treatment initiated

GLUTARIC ACIDEMIA TYPE 1

- Autosomal recessive disorder resulting in defect in the catabolic pathway of lysine, hydroxylysine and tryptophan
- > **Enzyme Defect:** Glutaryl-CoA Dehydrogenase (on chromosome 19)
- Clinical Presentation: Macrocephaly at birth, normal development until illness or metabolic stressor
 - ➤ → hypotonia and dystonia 'mimics acute onset CNS infection*
 - CT/MRI brain findings are present at birth (see images next)
 - > Can cause subdural hematomas and retinal hemorrhages

Diagnostic Test


- ➤ Urine organic acids: ↑ glutaric acid and 3-hydroxyglutaric acids
 - Plasma carnitine levels are low
- > Prenatal diagnosis: increased concentrations of glutaric acid in amniotic fluid DNA test preferred
- Treatment: L-carnitine, riboflavin & special diet
 - When acutely ill provide IV fluids containing glucose
- > Long term Prognosis: Mild growth failure, learning disabilities and verbal dyspraxia
 - > 5% of patients will be asymptomatic
 - > 35% of patients will have severe disease despite optimal therapy

HOMOCYSTINURIA

- Autosomal recessive disorder of methionine metabolism
- > **Enzyme Defect:** Cystathionine β -synthetase (chromosome21q)
- Screening YES (Elevated methionine)
- Clinical Presentation: Marfanoid habitus, developmental delay, downward /medial lens dislocation, osteoporosis and increased risk of arterial/venous thromboembolism
 - Presents within first 10years

Diagnostic Test

- Blood and urine test for excess homocysteine and methionine. Low level of cysteine
- Liver biopsy and enzyme assay for enzymatic activity
- Treatment: Large doses of pyridoxine (B6), B12 and folic acid. Diet low in methionine
 - Supplementation with Betaine
- Long term Prognosis: Intellectual disability is fairly common



ORGANIC ACID DISORDERS

PROPIONIC ACIDEMIA

- > Autosomal recessive defect in propionyl CoA carboxylase
- Clinical Presentation: Neonatal onset: Lethargy and coma
- Lab Findings: 个个ammonia, anion gap metabolic acidosis, neutropenia, thrombocytopenia,
 hyperglycinemia

Diagnostic Test

- Elevated propionyl carnitine.
- Plasma amino acid: ↑ Glycine
- ➢ Urine organic acid: ↑ Methylcitrate
- Enzyme assayon leukocytes

> Treatment:

- > Diet
- Carnitine
- Biotin (Cofactor forenzyme)

ISOVALETIC ACIDEMIA

- > Autosomal recessive defect in leucine metabolism
- Enzyme Defect: Isovaleryl-CoA dehydrogenase deficiency
- Clinical Presentation: "Odor of sweaty feet"
 - Onset in newborn periods severe metabolic acidosis, ketosis with vomiting coma and death
 - > Onset in infancy- symptoms are preceded by an infection or increased protein intake
 - Subsequent chronic intermittent pancytopenia and acidosis
- FL State Newborn Screen YES
- Diagnostic Test
 - > Urine organic acids
 - Prenatal diagnosis is possible

> Treatment:

- Acute: IV glucose
- > Chronic: Restricting leucine intake and prescribing carnitine &/or glycine

METHYLMALOMOIC ADODEMIA

- Autosomal recessive disorder that ultimately inhibits methylmalonyl-CoA mutase function.
- > 1/55,000 live births in the Finland
- > Enzyme Defect: Mutase deficiency and Cobalamin A, B, C, D, F and X deficiency
- > Clinical Presentation: Early: hyperammonemia, ketoacidosis and thrombocytopenia
 - Late onset: complication is renal failure and cardiomyopathy

Diagnostic Test

- Urine organic acids (increased methylmalonic acid and abnormal ketone bodies)
- Elevated homocysteine levels
- Treatment: Restriction of dietary protein. Betaine and IM B₁₂ vitamin only for cobalamin C, E and some D deficiencies
 - > Liver and kidney transplants may be curative

UREA CYCLE DEFECTS

Urea Cycle Defects	Incidence/ Inheritance	Deficiency	Symptom Onset	Presentation	Labs	
OPSDeficiency	1:70-100,000 AR	Carbamoyl phosphate synthetase I	By 5 days of age	Lethargy, hypotonia, vomiting and poor feeding Death if undiagnose d	 ↑Ammonia ↑CSF Glutamine Respiratory alkalosis Low BUN ↑Glutamine, alanine, asparagine ↓Citrulline ↓Argninine ↓Urine orotic acid 	Constant Consta
Ornithine Transcarbamylase (OTC) Deficiency	1:70,000 <mark>X-linked</mark> (Most common)	Ornithine Transcarbamylase	24-48 hours	Lethargy, hypotonia, vomiting and poor feeding Death if undiagnose d	↑Ammonia ↑CSF Glutamine Respiratory alkalosis Low BUN ↑Glutamine, Alanine, Asparagine ↓Citrulline ↓Argninine ↑Urine orotic acid	
Citrillinemia	AR	Arginoinosuccinate synthetase deficiency	Late onset; preceded by stressor		↑Ammonia ↓Argninine	
Argininosuccinic Aciduria	AR	Argininocuccinate lyase deficiency	Late onset; preceded by stressor	Trichorrhexis nodosa Episodic coma	↑Ammonia ↓Argninine	
Argininemia	AR	Arginase deficiency	Late onset; preceded by stressor	Progressive splastic diplegia, tremor, ataxia	↑Ammonia Normal Argninine	

Hyperlipoproteinemias

Type I Hyperlipoproteinemia

Lipoprotein Lipase Deficiency Increased Chylomicrons and VLDL Hypertriglyceridemia

Type II a

Hyperlipoproteinemia

Defect in LDL Receptors Increased LDL levels in blood Hyperbetalipoproteinemia Hypercholesterolemia

Type II b Hyperlipoproteinemia

Increased production of Apo B Increased production of VLDL and impaired LDL catabolism Increased VLDL and LDL **Spe III** amilial Dysbeta ipoproteinemias Defect in ApoE Broad Beta Disease Increased IDL

ype IV Hyper-pre-β-Lipoproteinemia Impaired VLDL metabolism. Increased VLDL Due to acquired conditions: Obesity Alcoholism Diabetes mellitus

Type V Combined Hyperlipoproteinemia

Increased VLDL and Chylomicrons Due to acquired conditions: Obesity □ Alcoholism **Diabetes mellitus**